Palatin Technologies, Inc. (0KF3) Earnings Call Transcript & Summary
May 16, 2023
Earnings Call Speaker Segments
Operator
operatorHello. Welcome to the conference call covering Palatin's operating results for the third quarter of fiscal year 2023. <<operator_script>> Please be aware that this call is being recorded. Before our remarks get underway, I want to note that any statements Palatin makes that are not historical facts could be forward-looking statements. Such statements rest on assumptions that might or might not turn out to be accurate, and actual results could differ materially from what is anticipated because of various risks and uncertainties covered in the company's latest filings with the Securities and Exchange Commission. When you evaluate these forward-looking statements about Palatin's prospects, please weigh those risks and uncertainties carefully. At this point I'd like to hand the call over to Dr. Carl Spana, Palatin's President and Chief Executive Officer. Please go ahead.
Carl Spana
executiveThanks. Morning, everyone, and glad to have you with us for Palatin's fiscal 2023 third-quarter call. I'm Dr. Carl Spana, the company's CEO and President. Joining me today is Steve Wills, who serves as Palatin's Executive Vice President, Chief Financial Officer and Chief Operating Officer. At this point I'll hand things over to Steve, and he'll walk you through the financial and operating update. Steve?
Steve Wills
executiveThanks, Carl. Hello, everyone. On the financial highlights, I'll begin with Vyleesi. Vyleesi is our FDA-approved commercial product for premenopausal women with hypoactive sexual desire disorder, or HSDD. The aim of the Vyleesi program is to show commercial product value in the marketplace, with an objective of licensing the U.S. rights to a committed women's health care company. For the third quarter ended March 31, 2023, gross product sales were $3.4 million, an increase of 31% over the prior quarter and an increase of 165% over the comparable quarter last year. Net product revenue of $1.2 million increased 16% over the prior quarter and increased 453% over the comparable quarter last year. Total prescriptions dispensed increased 27% over the prior quarter and increased 147% over the comparable quarter last year. We have achieved 5 consecutive quarters of double-digit growth. Refill rates, commercial insurance reimbursement and net revenue per prescription dispensed continued with positive and impactful results and trends versus the prior quarter and comparable quarter last year. We are particularly pleased that Vyleesi's quarterly net product revenue exceeds Vyleesi's quarterly operating expenses. Yes, that means we are not losing any money on Vyleesi. Also, we were issued a patent titled Use of Bremelanotide in Patients with Controlled Hypertension with a term through April 29, 2041.
Steve Wills
executiveOn the other item, Palatin did get $4.7 million in January 2023 through the State of New Jersey's Technology Business Tax Certificate Transfer program, which the New Jersey Economic Development Authority sponsors. Now shifting to the real financial operating results for the third quarter that ended March 31, 2023. On revenue, total revenue is made up of gross product sales of Vyleesi, net of allowances and accruals, plus license and contract revenue. I already went through the fee revenue and the Vyleesi revenue figures. On operating expenses, total operating expenses came to $8.5 million versus $8 million in the comparable quarter last year. That rise in operating expenses was primarily driven by greater spending on our marketing efforts for Vyleesi. On cash flows, Palatin's net cash used in operations was $1.4 million versus net cash used in operations of $9.5 million in the same period last year. The drop in net cash used in operations is mainly attributable to the company's receipt of proceeds from the State of New Jersey NOL, which stands for net operating losses; and to working capital changes for the quarter ended March 31, 2023. On net loss, Palatin's net loss was $7.1 million, or $0.63 per basic and diluted common share, versus a net loss of $7.6 million, or $0.80 per basic and diluted common share, in the comparable quarter last year.
Steve Wills
executiveThe smaller net loss versus the same quarter a year ago came primarily from a $1 million rise in net product revenue for Vyleesi, which was partly offset by roughly $500,000 in higher operating expenses. Turning to Palatin's cash position, as of March 31, 2023, cash and cash equivalents stood at about $19.6 million, along with approximately $1.7 million in accounts receivable. For comparison, cash and cash equivalents were $21.2 million with $6.5 million in accounts and other receivables as of December 31, 2022, and $29.9 million with $1.8 million in accounts receivable as of June 30, 2022. Under our current operating plan, we believe existing cash and cash equivalents and receivables will be enough to fund anticipated operating expenses through calendar year 2023. With that, I'll hand the call back to Carl.
Carl Spana
executiveThank you, Steve. Here at Palatin, our focus was on proving that the melanocortin system can serve as a target for safe investigative medicines aimed at inflammatory and autoimmune conditions, and on building a pipeline of highly effective drugs with safety that has no equal. Through work done in our own lab and alongside academic thought leaders, we keep deepening what we know about the melanocortin system so we can spot chances for new, innovative therapeutics. These research efforts help us design better clinical trials and are becoming an important support for our business development activities. We have 3 active clinical programs built on melanocortin agonists that came out of our research. On top of that, we have 2 new ocular programs ready, awaiting resources to kick off the activities needed to launch clinical studies. We are actively enrolling patients in the following clinical trials: MELODY-1, a Phase III study in dry eye disease; a Phase II study evaluating oral PL8177, a selective melanocortin-1 receptor agonist in ulcerative colitis patients; and breakout, a Phase II study in diabetic patients with kidney disease. We expect data readouts from all 3 clinical studies in calendar 2023. Turning to some of the third quarter highlights. Vyleesi keeps delivering impressive growth — as Steve mentioned, 5 quarters of double-digit increases across every key metric — and we expect that growth to continue.
Carl Spana
executiveWe keep achieving meaningful strides toward positioning the melanocortin system as a novel therapeutic target for treating numerous inflammatory conditions. As I mentioned, 3 clinical studies now have patients enrolling. Our ocular initiatives delivered some notable gains during this quarter. The developing product profile for PL9643 — our melanocortin-based dry eye disease therapy — has us genuinely enthusiastic. PL9643 stands sharply apart from existing options thanks to outstanding ocular tolerability and wide-ranging efficacy that we expect will position PL943 as the top dry eye disease treatment. At the Annual Meeting of the Association for Research in Vision and Ophthalmology, we shared findings from our analysis of the leading population in the PL9643 MELODY-1 Phase III trial. Across multiple dry eye disease signs and symptoms, PL9643 showed broad efficacy with statistical separation, along with an outstanding ocular tolerability and safety profile and no ocular adverse events. That analysis mattered greatly — it let us confidently finalize the primary sign and symptom endpoints, the ordering of secondary endpoints, the analysis methods and the sample size for the double-blind segment of the MELODY-1 Phase III trial. We additionally held a key opinion leader event for investors, where the highly encouraging MELODY-1 Phase III trial data was presented.
Carl Spana
executiveIn case you missed this event, a replay link is available on our website. We also presented data at ARVO regarding PL9588, which is a melanocortin-based treatment for glaucoma. In preclinical rapid studies, PL9588 demonstrated competitive effects on intraocular pressure — a single topical dose reduced intraocular pressure by a magnitude comparable to or larger than the positive controls latanoprost and timolol, with the effect persisting for as long as 24 hours. This important program is now prepared to move into pre-IND activities en route to clinical trials. Our non-ocular melanocortin programs likewise achieved meaningful progress, with multiple presentations at scientific meetings and publications in peer-reviewed journals, and we continue enrolling patients in Phase II trials. Our know-how regarding the melanocortin system and our innovative clinical programs are underpinning our business development efforts. Conversations with prospective partners for our programs have grown, and we stay optimistic that we will secure one or more partnerships to move our programs forward. Thank you for listening to the Palatin Third Quarter Fiscal 2023 Conference Call. More information about our science and clinical programs is available on our website, www.palatin.com. Additional information about Vyleesi can also be found at the vyleesi.com website.
Carl Spana
executiveSteve and I want to express our thanks to you, and at this point we'll open up the call for questions.
Operator
operator<<operator_script>> Today's first question comes from Joe Pantginis of H.C. Wainwright.
Joe Pantginis
analystLet me begin with Vyleesi. It's really encouraging to see the early momentum continuing there. I'm wondering, what percentage of inventory do you typically hold in the distribution centers? And what are your current plans, or the efforts already underway, to improve your gross-to-net at this stage?
Steve Wills
executiveJoe, this is Steve — thanks for raising that. Given how our distribution model works, we really just rely on a single specialty pharmacy, which is NPR. What happens is we sell to the NPR 3PL, and from there the NPR 3PL, so to speak, sells on to the pharmacy. In my view, we do a very solid job of ensuring that the dispenses we record for the month and for the quarter line up essentially with the sales, and that's the basis on which we report. So in the first quarter, March 31, '23, prescriptions dispensed came to slightly under 4,000 for that quarter, and that's essentially the amount we had sold to the 3PL. As a result, the gap there is only a point or 2. In short, there's virtually nothing sitting in the distribution chain that hasn't already been sold.
Joe Pantginis
analystYes, that’s right — please go ahead, and sorry about that.
Steve Wills
executiveThen as for part b of your question — what else are we doing — well, our strategy, as we've made very clear, is that we aren't aiming to deploy large numbers of salespeople, feet on the ground, so to speak. What we're targeting is a highly informed, carefully measured digital and social media campaign. We devote considerable time to making sure we've got the right algorithms, so to speak, so that when patients search for this condition and a treatment option, they find Vyleesi. We do have a handful of sales folk, though they're mostly inside and remote, even if they do travel a little. So we'll keep going with digital and social media. Since our metric is to demonstrate value — to let somebody, upon review, become very comfortable extrapolating the numbers from what we're doing — we believe we can do that; we can show it. From our target model standpoint, it's been successful. We've had five consecutive quarters of double-digit growth. That holds at the net sales level and also for prescriptions dispensed. We are growing demand, but that isn't our top metric.
Steve Wills
executiveOur goal was to ensure we secured substantial insurance coverage, making it as successful as possible for the patient. At this point, more than 2/3 of all our dispensers are covered by insurance. For 3/4 of those dispenses, the patient actually pays 0. So we believe we have quite robust insurance coverage in that regard. So we're going to keep on that path, Joe, which is raising demand a bit and making sure that our net -- gross to net number is good. And we've now reached the position where we aren't losing any money on Vyleesi. And we look forward to the time when someone sees the value that we've had yield, and we end up doing a licensing collaboration or selling the asset at some point in the future.
Joe Pantginis
analystNo. Great, I appreciate that additional detail. So here's what I'll do for my second question — I'm going to skip dry eye, since you just recently held a KOL event on that topic. Instead, I'll ask a quick question about 8177 for ulcerative colitis. I'm just curious: when you announce that first data set later this year, what kind of metrics might we potentially be given?
Carl Spana
executiveJoe, Carl here. So what we have is mainly a proof-of-concept trial, and imaging is really how it's carried out. They'll be doing a colonoscopy, and we're examining biopsy along with decreases in inflammation and lesion damage. It's a straightforward MAYO score. You also pick up other things, such as reductions in these tools and other standard measures that get used in these trials. But chiefly — this really is a study seeking direct evidence that the inflammation and damage happening in the colon are being reduced.
Operator
operatorThe next question today comes from Michael Higgins at Ladenburg Thalmann.
Michael Higgins
analystCongrats once more on everything moving forward with the pipeline this spring. You've definitely kept us on our toes. And thank you for arranging the KOL events. That was really useful. There isn't much that's new in the press release here. We have 2 questions. The first one follows Joe's line of thinking regarding what we're observing with the allowance for project returns. We see it as a fairly high percentage of gross sales. It appears to be sticking around there even given how long it's been since launch. Naturally, it covers possible returns. It could also reflect expiration dates along with financial overstocking, of course. So it's surprising that the rate on gross sales has stayed this elevated for this long. I'm just hoping to understand the reason for that and then, more significantly, when it could decline, since that would speed up reported net sales.
Carl Spana
executiveYes, Michael, I'm not quite sure I'm tracking what you're asking about stickiness or gross sales. The thing is, our gross sales go up each quarter. Net sales rise, for the most part, quarter after quarter, and that's why we're seeing double-digit growth. Our allowances for returns are very small, since returns aren't a big factor for us. So if you wouldn't mind clarifying the question a little more, I'd appreciate it. But to repeat, we have our gross and net sales each quarter. Apart from the first quarter, the spreads are improving. On the difference — net sales did have a lower yield in the first quarter, though that was 100% attributable to the first quarter. Insurance reimbursement came in lower, mainly because of the deductibles that typically hit during the first quarter, the first half of the year. And looking at the second quarter, we're back up to where we were before.
Michael Higgins
analystSure. Also, product returns are an accounting metric that has been applied across every product launch, and it gives investors—or anyone, I suppose—along with the accountants some insight into what could potentially come back as a return, and it's heavily regulated. It's not—it's a highly subjective thing, but it comes straight from dating and then also just returns, from what's coming back. A pharmacy might overorder, and then it gets sent back. Normally, that fades after the first, let's say, 12 months. But we're beyond that point now. So it still being elevated is a little surprising. We haven't modeled it. We're fairly conservative on that. But eventually, it comes down. Right now, roughly 75% of gross sales is along to product returns. At this point in the launch, we're at that level. Typically, it's under half. So at some stage, that should reverse, and when it does, that impacts net sales. It's a big accelerator. So I'm just trying to gauge when that might arrive.
Carl Spana
executiveI can assist if a shortage ever arises, but it won't happen. What you're citing isn't correct — 100% not correct. Our channel holds 0. The 3PL we sell through basically purchases only what's required for that week, driven by the volume heading to the pharmacy. And we can operate that way because we have just one pharmacy, and on the distribution side we have a single 3PL, with both located in the same industrial park, which is NPR. I can't emphasize this enough — I have no issue saying it — that information is 100% inaccurate. We don't expect or anticipate any meaningful allowances coming back. There is nothing in the channel that would cause that, and in fact our patient returns for the product are very, very low.
Michael Higgins
analystYes. I'm only looking at the 10-Q this morning, so that's what I'm going by. But I appreciate the feedback on that. Carl, one question for you. We're seeing quite a bit in the melanocortin pipeline moving forward, of course, in ophthalmic conditions. You've moved into ulcerative colitis and diabetic nephropathy. Vyleesi, obviously, has approval in female sexual dysfunction. We're just curious about what's possible in the BCD, given the rationale there and some of the success seen with melanocortin agents.
Carl Spana
executiveSure. Mike, we've discussed this in the past. Obviously, obesity and MCR4 — obesity — matters a great deal to the company and, without question, to me personally. We've put substantial resources into that area. And given how widely the GLP-1 inhibitor class has spread across the market and the potential multi — well, $100-plus billion market there, we are definitely taking an active look at what our options are in that space. Our view rests on our research work and very recent conversations with GLP-1 prescribers: we believe melanocortin agonist has a highly key and important role to play in treating obesity. And we're evaluating that. And I'd suggest you'll hear more on it over the coming quarters as that plan reaches finalization. But we're very interested in that. And we do think it's a phenomenal opportunity.
Operator
operator<<operator_script>> That wraps up the question-and-answer portion, and at this point I'll hand things back to management for their closing comments.
Carl Spana
executiveSteve, I believe, wants to say a few words briefly.
Steve Wills
executiveYes. On Michael Higgins' question about allowances and accruals, what he's really pointing to is in our 10-Q — specifically in the notes, Note 3, where we separate gross sales from net sales. For the 3 months ended March 31, '23, gross sales came to $3.4 million. Net sales were $1.2 million. The gap between them is what it costs us to move from gross to net. We show a lack of $899, but we also have to pay fees to the pharmacies, fees — reimbursement, if you will — to the PBMs, to the various insurance coverage, plus all the other very standard and customary expenses incurred in going from gross to net. There is 100% very little, if any, no charges tied to allowances that come back. And in fact, if you look at our March 31, 2023, quarter, net sales as a percentage of gross sales actually went up. The provision for all the various expenses was approximately 80% in the first quarter of March of '22, and it has now fallen to 65% for the first quarter of '23. Very significant increases, all positive. So I just wanted to clear that up, if you didn't mind.
Steve Wills
executiveThanks. Over to you, Carl?
Carl Spana
executiveThanks, Steve. I want to express my appreciation to all of you for joining the Third Quarter Fiscal 2023 Call. Steve and I are as excited as we could possibly be about what we're doing. It was a tremendous quarter, with progress across all the programs. I think we really seem to be hitting it pretty well right now, and we're quite enthusiastic about the future and what the rest of the year is going to bring. So with that being said, thank you all for participating. We'd like -- Steve and I would like you to have a great day, and we look forward to continue updating you on our progress and on the rest of 2023. So thank you.
Operator
operatorThat brings us to the end of today's call. You're welcome to drop off your lines now. Thanks for joining us.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Palatin Technologies, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Palatin Technologies, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Palatin Technologies, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.